alexa Cost-effectiveness Analysis Of Additional Bevacizumab To Chemotherapy For Malignant Pleural Mesothelioma From A Chinese Perspective
ISSN: 2167-065X

Clinical Pharmacology & Biopharmaceutics
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

4th International Pharma & Clinical Pharmacy Congress
November 07-09, 2016 Las Vegas, Nevada, USA

Mei Zhan
West China Hospital, China
Posters & Accepted Abstracts: Clin Pharmacol Biopharm
DOI: 10.4172/2167-065X.C1.023
Abstract
Objective: To evaluate the cost-effectiveness of addition of bevacizumab to pemetrexed plus cisplatin (PC) for malignant pleural mesothelioma (MPM) following a phase III trial that show an overall survival (OS) benefit with the addition of bevacizumab. Methods: A Markov decision tree based on the mesothelioma avastin cisplatin pemetrexed study (MAPS) was created, comparing bevacizumab+PC to PC alone. Three health states (progression-free survival, progressive disease and death) were analyzed in a Markov model. The costs were calculated from the Chinese societal perspective. Results were reported in qualityadjusted life year (QALY) and incremental cost-effectiveness ratios (ICERs). Results: Bevacizumab+PC came at an ICER of $323343.46 per QALY, which are much more than the accepted willingness-topay (WTP) threshold of $23970.00 per QALY in China. Conclusions: Addition of bevacizumab to PC is not a cost-effective first-line treatment for MPM when compared with PC in China.
Biography

Mei Zhan has graduated from Sichuan University and currently working as a Clinical Pharmacist in West China Hospital of Sichuan University. She has published more than 17 papers in journals of repute.

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords